Conatus Pharmaceuticals Inc. (CNAT)
(Delayed Data from NSDQ)
$0.90 USD
+0.05 (5.88%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.90 USD
+0.05 (5.88%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Conatus (CNAT) Loss Narrower Than Expected in Q4, Sales Miss
by Zacks Equity Research
Conatus (CNAT) reports narrower-than-expected loss in Q4 while revenues marginally fall short of estimates. However, the top line shows a massive year-over-year increase.
What's in Store for Conatus (CNAT) This Earnings Season?
by Zacks Equity Research
Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q4. However, the company's portfolio lacks an approved product and its revenue generation.
Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss
by Zacks Equity Research
Conatus (CNAT) reports wider-than-expected loss in Q3. However, revenues significantly increased year over year.
What's in Store for Conatus (CNAT) This Earnings Season?
by Zacks Equity Research
Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q3. However, the company's current portfolio shows no approved product and revenue generation.
Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU
by Zacks Equity Research
Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.
Conatus Entrusts Keith W. Marshall With Key Management Roles
by Zacks Equity Research
Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.
Non-Alcoholic Steatohepatitis 2017 Progress Update
by Zacks Equity Research
Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).
Will Conatus Liver Disease Candidate Drive Long-Term Growth?
by Zacks Equity Research
Conatus' (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in the company's portfolio are a positive step toward driving growth.
Conatus (CNAT) Up 7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Conatus (CNAT) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Conatus Key Candidate Emricasan Drive Long-Term Growth?
by Zacks Equity Research
Conatus's (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in its portfolio are a positive step by the company to propel growth.
Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Conatus (CNAT) reports wider-than-expected loss in Q2. However, revenue beat estimates, courtesy higher collaboration benefits.
What's in Store for Conatus (CNAT) this Earnings Season?
by Zacks Equity Research
Conatus' (CNAT) aim to progress with its lead candidate emricasan might boost the stock in Q2 results, although the company's current portfolio shows no approved product and revenue generation.
Company News for June 27, 2017
by Zacks Equity Research
Companies in the News are: SCHN,ARNC,CAR,CNAT
Conatus's PSC Candidate Gets Orphan Designation in the U.S.
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) announced FDA's grant of Orphan Drug Designation (ODD) to its pipeline candidate IDN-7314 for treatment of primary sclerosing cholangitis.
Conatus (CNAT) Down 33.1% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death
by Arpita Dutt
Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.
Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) is scheduled to report first-quarter 2017 results, after market closes. The company incurred wider-than-expected loss in the last quarter.
Kite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards?
by Zacks Equity Research
Kite Pharma, Inc. (KITE) is expected to report first-quarter 2017 results on May 8 before the market opens.
Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) is expected to report first-quarter 2017 results later this month.
Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) is scheduled to report first-quarter 2017 results on May 9, after the market closes.
Is ImmunoGen (IMGN) Poised for a Beat this Earnings Season?
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) is scheduled to report first-quarter 2017 results on May 5, before the opening bell.
Can Conatus Pharma (CNAT) Deliver a Beat in Q1 Earnings?
by Zacks Equity Research
We expect Conatus Pharmaceuticals Inc. (CNAT) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.
Conatus (CNAT) Catches Eye: Stock Moves Up 10% in Session
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) moved big last session, as its shares rose almost 10% on the day.
Conatus (CNAT) Up 57.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.